Literature DB >> 30589965

Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.

Tadayuki Oshima1, Eitatsu Arai2, Masato Taki1, Takashi Kondo1, Toshihiko Tomita1, Hirokazu Fukui1, Jiro Watari1, Hiroto Miwa1.   

Abstract

BACKGROUND: Proton pump inhibitors (PPIs) are widely used to treat gastro-oesophageal reflux disease (GORD). However, the onset of action is considered slow and PPIs cannot completely block acid secretion at night. A new potassium-competitive acid blocker (P-CAB) can rapidly block acid secretion. However, whether this P-CAB can relieve GORD symptoms quickly and adequately soon after starting treatment is unknown. AIM: To determine how rapidly vonoprazan and lansoprazole provide heartburn relief.
METHODS: Patients (n = 32) with endoscopically confirmed erosive oesophagitis who experienced heartburn at least once a week were randomised in a double-blind manner to receive either daily vonoprazan (20 mg) or lansoprazole (30 mg) before breakfast for 14 days. Day time and night time heartburn were assessed daily throughout the study using a five-point Likert scale. The primary endpoint was the first day of complete day and night heartburn relief for at least seven consecutive days. The ethics committees of the participating institutions approved the study protocol.
RESULTS: Heartburn was relieved sooner with vonoprazan than with lansoprazole (P < 0.05, log-rank test). Heartburn was completely relieved in 31.3% and 12.5% of patients on day 1 with vonoprazan and lansoprazole, respectively. Significantly more patients achieved complete nocturnal heartburn relief with vonoprazan than lansoprazole (P < 0.01). Both regimens were well tolerated.
CONCLUSIONS: Complete sustained heartburn relief was achieved sooner with vonoprazan than with lansoprazole during the first week of therapy. (UMIN000018776).
© 2018 John Wiley & Sons Ltd.

Entities:  

Year:  2019        PMID: 30589965     DOI: 10.1111/apt.15062

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  13 in total

1.  Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD.

Authors:  Yuta Yokoya; Ataru Igarashi; Akihito Uda; Hisato Deguchi; Toshihisa Takeuchi; Kazuhide Higuchi
Journal:  J Gastroenterol       Date:  2019-08-08       Impact factor: 7.527

Review 2.  Efficacy, safety and cost-effectiveness of vonoprazan vs Proton Pump Inhibitors in reflux disorders and H. pylori eradication: A literature review.

Authors:  Muhammad Shehryar; Rana Uzair Ahmad; Hira Khalid Kareem; Laiba Khan; Muhammad Fawad Ashraf; Ahtizaz Hassan; Sabeena Saeed; Haseeb Khan Tareen; Dr Adnan Nazir; Muhammad Aizaz Ashraf
Journal:  Ann Med Surg (Lond)       Date:  2022-09-22

3.  A comparison between dexlansoprazole modified release-based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial.

Authors:  Wei-Chen Tai; Chih-Ming Liang; Kuo-Wei Bi; Chung-Mou Kuo; Lung-Sheng Lu; Cheng-Kun Wu; Shih-Cheng Yang; Yuan-Hung Kuo; Chen-Hsiang Lee; Chih-Fang Huang; Chien-Ning Hsu; Pin-I Hsu; Deng-Chyang Wu; Tsung-Hui Hu; Keng-Liang Wu; Seng-Kee Chuah
Journal:  Infect Drug Resist       Date:  2019-09-16       Impact factor: 4.003

4.  Is a proton-pump inhibitor necessary after endoscopic submucosal dissection for superficial esophageal neoplasms? A propensity score analysis.

Authors:  Hideaki Kanaoka; Taro Iwatsubo; Toshihisa Takeuchi; Yuichi Kojima; Yoshiaki Takahashi; Akitoshi Hakoda; Shinya Nishida; Shinpei Kawaguchi; Kazuhiro Ota; Masatsugu Shiba; Kazuhide Higuchi
Journal:  Therap Adv Gastroenterol       Date:  2020-11-24       Impact factor: 4.409

Review 5.  Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art.

Authors:  Vincenzo Savarino; Elisa Marabotto; Patrizia Zentilin; Maria Giulia Demarzo; Nicola de Bortoli; Edoardo Savarino
Journal:  Drug Des Devel Ther       Date:  2021-04-19       Impact factor: 4.162

6.  Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: A cost-effectiveness analysis in Japan.

Authors:  Yasuki Habu; Ryuhei Hamasaki; Motonobu Maruo; Tatsuya Nakagawa; Yuki Aono; Daisaku Hachimine
Journal:  J Gen Fam Med       Date:  2021-02-21

Review 7.  Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021.

Authors:  Katsuhiko Iwakiri; Yasuhiro Fujiwara; Noriaki Manabe; Eikichi Ihara; Shiko Kuribayashi; Junichi Akiyama; Takashi Kondo; Hiroshi Yamashita; Norihisa Ishimura; Yuichi Kitasako; Katsunori Iijima; Tomoyuki Koike; Nobuo Omura; Tsutomu Nomura; Osamu Kawamura; Shuichi Ohara; Soji Ozawa; Yoshikazu Kinoshita; Satoshi Mochida; Nobuyuki Enomoto; Tooru Shimosegawa; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2022-02-28       Impact factor: 7.527

Review 8.  Current knowledge on non-steroidal anti-inflammatory drug-induced small-bowel damage: a comprehensive review.

Authors:  Toshio Watanabe; Yasuhiro Fujiwara; Francis K L Chan
Journal:  J Gastroenterol       Date:  2019-12-21       Impact factor: 7.527

9.  Evaluations of Gastric Acid Pocket Using Novel Vertical 8-Channel pH Monitoring System and Effects of Acid Secretion Inhibitors.

Authors:  Shohei Sumi; Norihisa Ishimura; Hironobu Mikami; Eiko Okimoto; Yuji Tamagawa; Tsuyoshi Mishiro; Yoshikazu Kinoshita; Shunji Ishihara
Journal:  J Neurogastroenterol Motil       Date:  2021-07-30       Impact factor: 4.924

Review 10.  Design characteristics of comparative effectiveness trials for the relief of symptomatic dyspepsia: A systematic review.

Authors:  Natalie Elliott; Amie Steel; Bradley Leech; Wenbo Peng
Journal:  Integr Med Res       Date:  2020-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.